September 17, 2012
On September 13, Dr. Dolinar presented on two panels at the DIA/FDA Biosimilars Conference: Guidances, Science, and BsUFA in Washington, D.C. His first panel was on Pharmacovigilance, Naming, and Labeling and the second panel was on Interchangeability. DIA Presentation on Biosimilar Naming DIA Presentation on Interchangeability During the conference, ASBM released a new survey examining […]
June 28, 2012
On June 4, Alliance Chairman Dr. Richard Dolinar and Executive Director Michael Reilly presented at the Canadian Patient Experts in Health Technology forum in Toronto, Canada. The forum was organized by Durhane Wong-Rieger, president of the Canadian Organization for Rare Disorders. The two-day event was set up to establish a global network of individual patient […]
April 18, 2012
On February 27, 2012, the Alliance for Safe Biologic Medicines and Bloomberg Government hosted a lunch time Biosimilars Forum on Capitol Hill to discuss the FDA’s draft guidance documents on biosimilar product development.
October 5, 2011
By Kathy Feegal Dr. Richard Dolinar, the Alliance’s chairman, was a keynote speaker at a biosimilars roundtable discussion in Boston, MA on October 5, 2011. The event was hosted by Northeastern University and was attended by numerous stakeholders from across New England, including the Massachusetts Medical Society, and patients groups such as the National Kidney […]
September 28, 2011
The Alliance for Safe Biologic Medicines joined with the Virginia Biotechnology Association at an event to expore with patients, advocates, physicians and other healthcare providers the importance of maintaining patient safety as the U.S. FDA’s top priority while it works to establish a pathway for approval for biosimilar products.
August 17, 2011
The Alliance for Safe Biologic Medicines and Pennsylvania Bio hosted an event entitled, “Biosimilars Policy Forum: Ensuring Patient Safety” in Philadelphia, PA, on August 17, 2011 The purpose of the forum discussion was to explore with community members, including policymakers, patients, physicians, pharmacists, and hospital officials the importance of maintaining patient safety as the U.S. […]
